Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP6V1B1 | P15313 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | EZH2 | Q15910 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6581522 | 0.89 | HTR4 (0.39) | ATP6V1B1KMT2AMEN1HTR4 | |
| SCHEMBL6582988 | 0.88 | MEN1 (0.54) | ATP6V1B1KMT2AMEN1PKMATM | |
| SCHEMBL5649899 | 0.83 | KMT2A (0.46) | ATP6V1B1KMT2AMEN1PKMHSD17B10 | |
| SCHEMBL220979 | 0.78 | KMT2A (0.51) | ATP6V1B1KMT2AMEN1PKML3MBTL1 | |
| SCHEMBL14341046 | 0.78 | MEN1 (0.51) | ATP6V1B1KMT2AMEN1PKMATM | |
| SCHEMBL6582339 | 0.78 | MEN1 (0.57) | ATP6V1B1KMT2AMEN1ATML3MBTL1 | |
| SCHEMBL6582686 | 0.77 | MEN1 (0.48) | ATP6V1B1KMT2AMEN1PKMATM | |
| SCHEMBL6439903 | 0.77 | MEN1 (0.41) | ATP6V1B1KMT2AMEN1PKMEZH2 | |
| SCHEMBL6583437 | 0.77 | KDM4E (0.41) | KMT2AMEN1HSD17B10POLB | |
| SCHEMBL6582589 | 0.77 | MEN1 (0.49) | ATP6V1B1KMT2AMEN1PKML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235930-A1 | Indole derivatives and their use for the treatment of osteoporosis amongst other applications | FARINA CARLO (IT) | 2004-11-25 | — | — | US | claimed |
| EP-1212317-B1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | NIKEM RESEARCH SRL (IT) | 2004-09-15 | — | — | EP | claimed |
| US-6787550-B1 | 4-(5,6-DICHLORO-1H-INDOL-2-YL)-3-ETHOXY-N-(2,2,6,6 -TETRAMETHYLTETRAMETHYLPIPERIDIN-4-YL)-BENZAMIDE | NIKEM RESEARCH S.R.L. (IT) | 2004-09-07 | — | — | US | claimed |
| EP-1212317-A1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | GlaxoSmithKline S.p.A. (IT) | 2002-06-12 | — | — | EP | claimed |
| WO-2001002388-A1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | GLAXOSMITHKLINE S.P.A. (IT) | 2001-01-11 | — | — | WO | claimed |
| EP-1212317-B1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | NIKEM RESEARCH SRL (IT) | 2004-09-15 | — | — | EP | disclosed |
| US-6787550-B1 | 4-(5,6-DICHLORO-1H-INDOL-2-YL)-3-ETHOXY-N-(2,2,6,6 -TETRAMETHYLTETRAMETHYLPIPERIDIN-4-YL)-BENZAMIDE | NIKEM RESEARCH S.R.L. (IT) | 2004-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235930-A1 | Indole derivatives and their use for the treatment of osteoporosis amongst other applications | MALT1, SOST, NFATC1 | ATP6V1B1 401/4885KMT2A 3757/4885MEN1 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.